BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/13/2018 8:04:45 AM | Browse: 1065 | Download: 1546
 |
Received |
|
2018-07-05 00:38 |
|
Peer-Review Started |
|
2018-07-05 02:26 |
|
To Make the First Decision |
|
2018-08-27 02:25 |
|
Return for Revision |
|
2018-08-28 02:47 |
|
Revised |
|
2018-09-27 13:07 |
|
Second Decision |
|
2018-10-15 08:43 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-10-15 18:25 |
|
Articles in Press |
|
2018-10-15 18:25 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-11-09 05:53 |
|
Publish the Manuscript Online |
|
2018-11-13 08:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sara Cabrero-de las Heras and Eva Martinez-Balibrea |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| ISCIII |
PI16/01800 and PIE16/00011 |
|
| Corresponding Author |
Eva Martinez-Balibrea, PhD, Senior Scientist, Program against Cancer Resistance (ProCURE) Catalan institute of oncology, Germans Trias i Pujol health research institute (IGTP), Carretera de Can Ruti, camí de les escoles s/n, Badalona, Barcelona 08916, Catalunya, Spain. embalibrea@iconcologia.net |
| Key Words |
Biomarkers; Treatment; Chemotherapy; Oxaliplatin; Irinotecan; Immunotherapy; Colorectal cancer; CXC chemokines; Immune system; Bevacizumab |
| Core Tip |
The contribution of the immune system to the development and progression of cancer is now fully acknowledged. The specific action of the immune system depends on the type of immune cells that are recruited to the tumor sites. Chemokines from the CXC subfamily are released by tumor cells and cells within the tumor microenvironment, whereupon they attract cells with anti-tumor (e.g., CD4+ and CD8+ lymphocytes) or pro-tumor activity (e.g., myeloid-derived suppressor cells). Chemokines have been proposed as prognostic factors, as biomarkers of response to therapy and as drug targets. The present review addresses the most recent findings in the field. |
| Publish Date |
2018-11-13 08:04 |
| Citation |
Cabrero-de las Heras S, Martínez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol 2018; 24(42): 4738-4749 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i42/4738.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i42.4738 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
